Press Release: CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones11-09

Presentation and publication of clinical and biomarker data, regulatory developments,

and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies

Rapidly advancing neflamapimod for the treatment of nonfluent variant primary progressive aphasia; 24-week biomarker data selected for presentation at the 19(th) Annual Clinical Trials on Alzheimer's Disease Conference (CTAD 2026)

BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. $(CRVO)$, a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the third quarter ended September 30, 2026, and provided corporate updates.

"The Company believes that the neflamapimod clinical development program has been significantly de-risked through the presentation and publication of compelling, supportive datasets throughout this year and the ability to advance the 100mg BID dosing regimen, strengthening its position as a potential therapeutic for dementia with Lewy bodies and other devastating neurodegenerative disorders," stated John Alam, MD, Chief Executive Officer of CervoMed.

"As we look ahead to the remainder of the year and into 2027, we believe neflamapimod is well-positioned to succeed in the clinic, drive stockholder value, and ultimately, if approved, bring a transformative therapy to a market with massive, unmet medical needs. We have several upcoming milestones that we are working toward, including 24-week biomarker data from our Phase 2 clinical trial in patients with nonfluent variant primary progressive aphasia at CTAD 2026, Phase 2a data in recovery after stroke, and the commencement of dosing in ALS," concluded Dr. Alam.

Third Quarter 2026 and Recent Program Highlights

Dementia with Lewy Bodies $(DLB)$

   -- In July 2026, at the Alzheimer's Association International Conference 
      $(AAIC)$, CervoMed reported new clinical, plasma biomarker, and MRI imaging 
      data across five data presentations that highlighted insights into 
      neflamapimod's treatment effects in DLB. The data provide further 
      supportive evidence that neflamapimod has the potential to address the 
      underlying cause of DLB. The AAIC data presentations can be accessed 
      here. 
 
   -- In August 2026, neflamapimod was awarded Innovation Passport designation 
      under the United Kingdom Innovative Licensing and Access Pathway (ILAP) 
      for the treatment of DLB. The Innovation Passport is designed to support 
      accelerated time to market and help expedite patient access to 
      potentially transformative new investigational medicines. 
 
   -- In September 2026, CervoMed announced the pharmacokinetic properties of a 
      50mg oral tablet formulation of neflamapimod that will be utilized in 
      CervoMed's future clinical studies, as well as the United States (US) 
      Food and Drug Administration's (FDA) removal of a prior neflamapimod drug 
      exposure limit for future clinical trials. These advances support the use 
      of a 100mg BID dosing regimen in CervoMed's future clinical trials, which 
      the Company believes is the optimal dosing regimen and expects to achieve 
      target trough plasma drug concentrations in nearly all patients. 
 
   -- In October 2026, CervoMed announced the publication of two peer-reviewed 
      articles supporting neflamapimod as a potential treatment for DLB. The 
      placebo-controlled results of the Phase 2b RewinD-LB trial were published 
      in Alzheimer's Research & Therapy and translational findings, which 
      included extension phase biomarker data from the RewinD-LB trial showing 
      that neflamapimod modulates key neuroinflammatory processes implicated in 
      neuronal damage and cognitive decline in DLB, were published in Cells. 

Frontotemporal Dementia (FTD)

   -- In October 2026, CervoMed presented initial 12-week biomarker results 
      from its ongoing Phase 2a trial evaluating neflamapimod in patients with 
      nonfluent variant primary progressive aphasia (nfvPPA), a type of FTD, in 
      a late-breaking oral session at the 15th International Conference on 
      Frontotemporal Dementias. These preliminary data demonstrated a reduction 
      in mean plasma levels of neurofilament light chain, a key biomarker of 
      neuronal damage and degeneration. 24-week biomarker data from this Phase 
      2a trial have been selected for presentation at CTAD 2026, taking place 
      November 16-19, 2026 in Boston, Massachusetts. 

Recovery After Stroke (RAS)

   -- CervoMed recently completed enrollment of 45 patients in the Phase 2a 
      RESTORE trial evaluating neflamapimod in patients recovering from acute 
      ischemic stroke. 

Anticipated Milestones

CervoMed's anticipated milestones for the remainder of 2026 and early 2027 include:

   -- DLB: CervoMed will continue its efforts to advance the development of 
      neflamapimod as a treatment for DLB, including the Company's primary 
      strategic objective to establish a partnership to advance neflamapimod 
      into a Phase 3 clinical trial in patients with DLB, as well as its 
      continued evaluation of alternatives to finance the program. 
 
   -- FTD: CervoMed expects to report 24-week biomarker data from its ongoing 
      Phase 2a clinical trial evaluating neflamapimod in nfvPPA at CTAD 2026 in 
      mid-November 2026. The Company expects to report initial 24-week clinical 
      data, as well as additional biomarker data, at the Alzheimer's & 
      Parkinson's Diseases Conference in March 2027, and full topline data from 
      the trial in the second quarter of 2027. 
 
   -- ALS: CervoMed expects dosing of the first patient with neflamapimod in 
      the EXPERTS-ALS trial, which will evaluate neflamapimod for the treatment 
      of ALS, in the first quarter of 2027. 
 
   -- RAS: CervoMed expects to obtain topline data from its Phase 2a RESTORE 
      trial evaluating neflamapimod in patients recovering from acute ischemic 
      stroke by the end of 2026. 

Third Quarter 2026 Financial Results

Cash Position: As of September 30, 2026, CervoMed had approximately $19.6 million in cash, cash equivalents, and marketable securities, as compared to $20.9 million as of December 31, 2025. Based on its current operating plan, CervoMed believes its cash, cash equivalents, and marketable securities on hand as of September 30, 2026, will enable the Company to fund its planned operating expenses and capital expenditure requirements through the third quarter of 2027.

Grant Revenue: There was no grant revenue recognized for the three months ended September 30, 2026, compared to approximately $0.3 million for the same period in 2025. The decrease was due to the completion of CervoMed's Phase 2b RewinD-LB trial in mid-2025 and, accordingly, there currently being no further funding available or expected under the $21.3 million grant previously awarded to CervoMed by the National Institute on Aging to support the trial.

Research and Development (R&D) Expenses: R&D expenses for the three months ended September 30, 2026, were approximately $3.7 million, compared to approximately $6.0 million for the same period in 2025. The decrease was primarily due to lower costs related to the Company's completed RewinD-LB Trial, decreases in personnel costs, costs related to the CervoMed's ongoing Restore Trial in RAS, and other lower R&D costs. These decreases were partially offset by increases in costs related to the Company's ongoing Phase 2a clinical trial in nfvPPA and other clinical and nonclinical costs.

General and Administrative (G&A) Expenses: G&A expenses were approximately $2.4 million during the three months ended September 30, 2026, compared to approximately $2.3 million for the same period in 2025. The increase was primarily due to increases in personnel costs, stock-based compensation expense, and professional fees, the latter driven by added legal expenses for patent work, other corporate legal expenses, and consulting expenses. The increase was partially offset by lower costs associated with insurance, taxes, and similar fees.

Net Loss: Net loss was approximately $5.9 million for the three months ended September 30, 2026, compared to approximately $7.7 million for the same period in 2025. The decrease was primarily due to lower total operating expenses, partially offset by a decrease in grant revenue.

About Neflamapimod

Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and primary progressive aphasia.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment